In response to recent discussions concerning the use of Ozempic (semaglutide) for the treatment of obesity, the Belgian Association for the Study of Obesity would like to articulate its position on the matter.
Attached, you will find our comprehensive response that elaborates on this subject. Our stance is that the prescription of Ozempic aligns with the code of conduct that we have recommended for treating obesity accompanied by type 2 diabetes as a reimbursed indication. Physicians prescribing Ozempic for severe forms of obesity without type 2 diabetes do so based on professional judgment and in the best interest of their patients, in accordance with the Hippocratic Oath.
We call for a constructive dialogue involving all stakeholders to jointly find an effective approach for treating obesity. This is particularly crucial given that more than one-fifth of the adult population in Belgium is currently suffering from this condition. We urge healthcare providers, policy-makers, and the community at large to engage in conversations that contribute to shaping a comprehensive and ethical treatment regimen for obesity.
Download the PDF
English (UK) 
Nederlands (België) 
Français de Belgique